- CEO
- Han Jie Zheng
- Full Time Employees
- 1,154
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Shantou China
- IPO Date
- Mar 29, 2022
- Business
- Guangdong Taienkang Pharmaceutical Co., Ltd. is a China-based pharmaceutical and healthcare enterprise engaged in the research, development, manufacturing, marketing, and distribution agency of pharmaceuticals, active pharmaceutical ingredients (APIs), and medical devices. Founded in 1999 and headquartered in Shantou, Guangdong Province, the company operates across four primary business divisions: Proprietary Pharmaceuticals, Traditional Chinese Medicine (TCM), Medical Devices and Consumables, and Pharmaceutical Agency and Commercialization Services.
The company's core product and service portfolio comprises: sexual health and urology medications, including sildenafil citrate tablets (Eterda), tadalafil tablets (Eterway), dapoxetine hydrochloride tablets (Eterva), and combination finasteride and tadalafil capsules (Eterly); topical and dermatological formulations under the Wuhuan brand, including red flower oil, peppermint surface oil, compound ketoconazole cream, and external therapeutic ointments; ophthalmology and internal medicine treatments, including lecithin-bound iodine tablets (Woliting/Jolethin); Traditional Chinese Medicine preparations, including Hewei Zhengchang pills, Compound Black Chicken pills, Liuwei Dihuang pills, Xiaoyao pills, and the Tianfukang product line; medical consumables, including surgical and protective face masks, medical protective equipment, and in vitro diagnostic reagents; and agency distribution services providing comprehensive supply chain, regulatory management, and marketing channel access for domestic and international medical device and pharmaceutical manufacturers, including Johnson & Johnson. Taienkang distributes its products to hospitals, clinical centers, and retail pharmacy networks across more than 28 provinces in mainland China.
The company operates through subsidiaries including Shandong Huabo Kaisheng Biotechnology Co., Ltd., Jiangsu Bochuangyuan Pharmaceutical Co., Ltd., Sichuan Taienkang Pharmaceutical Co., Ltd., Shantou Wuhuan Pharmaceutical Factory Co., Ltd., and Ma'anshan Tianfukang Pharmaceutical Co., Ltd. In recent developments, Taienkang acquired a controlling majority stake in Jiangsu Bochuangyuan Pharmaceutical Co., Ltd., expanding its innovative drug pipeline with CKBA (3-O-acetyl-11-keto-beta-boswellic acid ointment), a first-in-class small-molecule candidate undergoing Phase II and Phase III clinical development for vitiligo, rosacea, and psoriasis. The company has also advanced its pipeline of improved drug formulations, progressing clinical trials for cisplatin polymer micelles for solid tumors and pilocarpine hydrochloride ophthalmic drops for presbyopia. Furthermore, Taienkang entered strategic cooperation discussions to integrate artificial intelligence into its drug discovery processes for oncology and autoimmune diseases, while expanding its production capacity through the construction and upgrading of active pharmaceutical ingredient workshops and finished dosage manufacturing facilities across Anhui, Sichuan, and Guangdong.